Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy（MD Anderson Cancer Center）

N/A

Report date: 2023/03/20 20:00:20

Base Information

Drug NameAutologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy（MD Anderson Cancer Center）
Drug Alias NameJV-213
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD79B
TargetsB-cell antigen receptor complex-associated protein beta chain
Therapy Area/IndicationsLymphoma, B-CellLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A